ArticleThe oncologist2020
The Predictive Value of Early Changes in
Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Progression-free survival prediction and comparative metastasis detection accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2026Pooled it
- The Role of Estrogen Receptor-Targeted PET with 16α-Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- 18F-fluoroestradiol positron emission tomography in patients with breast cancer: a systematic review and meta-analysis.Revista da Associacao Medica Brasileira (1992) · 2023Pooled it
- AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Nature communications · 2022Trial
- The Role of [Cancers · 2025Review
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Characterization of an Estrogen Receptor α-SelectiveWorld journal of nuclear medicine · 2024Article
- Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.Current oncology reports · 2024Review
- Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.Journal of clinical medicine · 2023Review
- Article
- Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer.MedComm · 2022Article
- Evaluation of tumour heterogeneity byBreast cancer research : BCR · 2022Article
- Gallium-68 Labeling of the Cyclin-Dependent Kinase 4/6 Inhibitors as Positron Emission Tomography Radiotracers for Tumor Imaging.ACS omega · 2021Article
- Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.Frontiers in oncology · 2020Article
- Molecular Imaging of Steroid Receptors in Breast Cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate the predictive value of early changes in MATERIALS AND
methodsPatients underwent
resultsIn total, 294
conclusionChanges in SUVmax measured by serial imaging of IMPLICATIONS FOR PRACTICE: The aim of this study was to evaluate the role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.